Akebia Therapeutics, Inc.
AKBA
$1.65
$0.106.45%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 160.18M | 169.88M | 174.50M | 187.23M | 194.62M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 160.18M | 169.88M | 174.50M | 187.23M | 194.62M |
| Cost of Revenue | 25.56M | 26.36M | 30.31M | 30.73M | 39.43M |
| Gross Profit | 134.62M | 143.52M | 144.19M | 156.50M | 155.20M |
| SG&A Expenses | 106.55M | 104.31M | 100.50M | 100.62M | 100.24M |
| Depreciation & Amortization | 36.04M | 36.04M | 36.04M | 36.04M | 36.04M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 205.80M | 202.44M | 207.42M | 220.52M | 238.78M |
| Operating Income | -45.62M | -32.56M | -32.93M | -33.29M | -44.16M |
| Income Before Tax | -69.41M | -45.99M | -40.44M | -43.03M | -51.92M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -69.41 | -45.99 | -40.44 | -43.03 | -51.92 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -69.41M | -45.99M | -40.44M | -43.03M | -51.92M |
| EBIT | -45.62M | -32.56M | -32.93M | -33.29M | -44.16M |
| EBITDA | -8.11M | 5.00M | 4.67M | 4.30M | -6.53M |
| EPS Basic | -0.33 | -0.22 | -0.20 | -0.22 | -0.28 |
| Normalized Basic EPS | -0.19 | -0.13 | -0.12 | -0.13 | -0.17 |
| EPS Diluted | -0.33 | -0.22 | -0.20 | -0.22 | -0.28 |
| Normalized Diluted EPS | -0.19 | -0.13 | -0.12 | -0.13 | -0.17 |
| Average Basic Shares Outstanding | 843.71M | 814.91M | 792.87M | 769.98M | 749.80M |
| Average Diluted Shares Outstanding | 843.71M | 815.51M | 793.46M | 770.58M | 750.39M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
